Navigation Links
K-V Pharmaceutical Company Announces Filing of Fiscal Year 2010 Annual Report on Form 10-K With the Securities and Exchange Commission
Date:12/27/2010

ST. LOUIS, Dec. 27, 2010 /PRNewswire-FirstCall/ -- K-V Pharmaceutical Company (NYSE: KVa/KVb) today announced the filing of its Form 10-K for its fiscal year ended March 31, 2010 with the Securities and Exchange Commission.  As a result, the Company has met the deadline for filing its delayed fiscal 2010 Form 10-K to enable its securities to continue trading on the New York Stock Exchange.

The Company is currently working on preparing and filing its quarterly reports on Form 10-Q for the quarters ended June 30, 2010 and September 30, 2010 and will file these reports as soon as they are completed.  The Company's Form 10-Q for the quarter ending December 31, 2010 will be due on February 9, 2011.  The Company currently expects that it will be unable to timely file this report.

Greg Divis, KV's Chief Executive Officer stated, "We are pleased to have filed our Form 10-K for fiscal 2010 and continue to work diligently and as quickly as possible to file the remaining outstanding quarterly reports to enable us to return to a current and timely filer with the Securities and Exchange Commission.  The Company continues to move forward as we focus on returning additional products to the market prior to our 2011 fiscal year-end and to the approval and launch of Gestiva™."

About K-V Pharmaceutical Company

K-V Pharmaceutical Company is a fully-integrated specialty pharmaceutical company that develops, manufactures, markets, and acquires technology-distinguished branded prescription pharmaceutical products.  The company markets its technology-distinguished products through Ther-Rx Corporation, its branded drug subsidiary.  For further information about K-V Pharmaceutical Company, please visit the company's corporate Web site at www.kvpharmaceutical.com.

Cautionary Note Regarding Forward-looking Statements

This press releases contains various
'/>"/>

SOURCE K-V Pharmaceutical Company
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)...  Hologic, Inc. (Hologic or the Company) (NASDAQ: ... and supplier of premium diagnostics, medical imaging systems ... the healthcare needs of women, today announced that ... clinical practice comparing breast cancer screening with Hologic,s ... mammography alone showed a significant reduction in recall ...
(Date:5/23/2013)... 23, 2013  BioElectronics Corporation (OTC Pink: BIEL), the ... on the FDA panel meeting for non-thermal shortwave diathermy: ... Pulsed Shortwave Therapy Meeting was held on May 21, ... The focus of the meeting was very narrow, in ... solely on the application of non-thermal shortwave diathermy for ...
(Date:5/23/2013)... YORK , May 23, 2013  Intercept Pharmaceuticals, ... stage biopharmaceutical company focused on the development and commercialization ... diseases, such as primary biliary cirrhosis, today announced that ... Chief Executive Officer, will present at the Deutsche Bank ... Boston on Wednesday, May 29, 2013 at ...
Breaking Medicine Technology:First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection 2First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection 3First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection 4BioElectronics and Pulsed Shortwave Therapy Make Progress 2
... Significant Improvement in Cognitive Performance and Global Clinical Status ... ... 30 Forest Laboratories, Inc.,(NYSE: FRX ) presented today positive ... at the 2008,Alzheimer,s Association International Conference on Alzheimer,s Disease,(ICAD). The study ...
... 30 Wound Care Innovations, LLC,a subsidiary of ... today an evidence based study with a NE ... wound care collagen,product, CellerateRx(R), on diabetic venous ulcers. ... Control and Prevention, diabetes now,affects nearly 24 million ...
Cached Medicine Technology:New Data Highlight Positive Results of Namenda(R) (memantine HCl) Once-Daily Extended-Release Formulation 2New Data Highlight Positive Results of Namenda(R) (memantine HCl) Once-Daily Extended-Release Formulation 3New Data Highlight Positive Results of Namenda(R) (memantine HCl) Once-Daily Extended-Release Formulation 4Wound Management Technologies, Inc. Announces Agreement for Evidence Based Study for Diabetic Venous Ulcers 2
(Date:5/23/2013)... CA (PRWEB) May 23, 2013 EnvirOasis, ... the contractor and ESCO market is pleased to announce ... Consortium (DLC) Listed LED products. EnvirOasis has been ... fixtures and retrofit kits and has recently brought ... LED (Light Emitting Diode) is energy efficient lighting ...
(Date:5/23/2013)... May 23 (HealthDay News) -- The sensation of itching ... traced back to a small molecule released in the ... mice. Researchers say this molecule, known as natriuretic ... the central nervous system. Ultimately, this signal is experienced ... and mice are similar, the researchers concluded that a ...
(Date:5/23/2013)... HealthDay Reporter , , THURSDAY, May 23 (HealthDay News) ... sharply, especially among Hispanic teens, according to a new government ... 15 to 19 dropped by nearly one half from 1991 ... teens to 31 births for every 1,000. From 2007 ... 25 percent, from 41.5 to about 31. During that ...
(Date:5/23/2013)... A shortage of a critical tuberculosis drug has hampered ... to contain the spread of the highly infectious lung ... was first used in 1951 and is one of ... first-line treatment for tuberculosis (TB). Patients must take the ... U.S. Centers for Disease Control and Prevention. However, ...
(Date:5/23/2013)... U.S. scientists have used virus isolated from a person ... whether the virus could infect and be transmitted between ... in influenza research, and efficient transmission of influenza virus ... the same process might occur in people. The research ... Allergy and Infectious Diseases, part of the National Institutes ...
Breaking Medicine News(10 mins):Health News:EnvirOasis Lighting Announces Energy Star and Design Lights Consortium LED Products 2Health News:Got an Itch? Mouse Study May Help Explain Why 2Health News:U.S. Teen Birth Rate Plummets: Report 2Health News:U.S. Teen Birth Rate Plummets: Report 3Health News:Shortage of Key Drug Hampering U.S. Efforts to Control TB: Report 2Health News:Ferrets, pigs susceptible to H7N9 avian influenza virus 2
... gum may increase the risk of the Alzheimer’s disease// ... ,According to a research study that is presented ... of Dementia held in US, periodontal conditions could affect ... disease affects the brain cells and slowly destroys them. ...
... than thought of and may remain undetected because of this//, ... arthritis of the spine is a disease that may affect ... and stiffness for a long time must be medically examined ... significant relief from the condition for the children. Some symptoms ...
... out that people who regularly drink large amount of alcohol are ... causes than binge drinkers, who drink a lot of alcohol in ... had more than enough attention given to young alcohol consumers who ... maximum, these people may be more at risk from violent assaults ...
... Researchers have shown that placebo treatment can reduce the ... uncommon experiences. ,Placebo treatment consists of dummy medication ... harmless tablets, saline water injections etc. ,In the ... researchers have shown that placebo treatment can effectively control ...
... the proper structure// and function of cell membranes and ... animal studies have shown that high intake of polyunsaturated ... is a clouding of the normally clear lens of ... of blindness in the world today. Besides the physical ...
... continuously for a short time can affect your memory ... on mice says that consuming alcohol daily for even ... and other cognitive functions like learning. Researchers from St. ... the memory gets affected; the cognitive impairment can remain ...
Cached Medicine News:Health News:PUFA reduces risk of cataract 2
... the world leader in peel-away introducers. ... for permanent pacemaker and defibrillator lead ... implantation, and for temporary pacemaker insertions. ... Medical Peel-Away introducers includes the Di-Lock™ ...
The RX HERCULINK® PLUS Biliary Stent System is Guidant's high performance .014" guide wire compatible system. It is available in stent diameters of 4.0-6.5mm for the 12mm stent length and 4.0-7.0...
... Supreme and Response catheters comprise the ... available for electrophysiology procedures. Their advanced ... for superior torque response with a ... curves and French sizes, Supreme and ...
... Supreme and Response catheters comprise the ... available for electrophysiology procedures. Their advanced ... for superior torque response with a ... curves and French sizes, Supreme and ...
Medicine Products: